| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
| ln Vitro |
At 3 μM and 30 μM, INDY (0.3-30 μM; 20 hours) virtually totally blocks tau phosphorylation [1]. Nuclear factor of activated T cells, or NFAT, signaling is blocked when acid-(Y)-phosphorylation regulator 1A is overexpressed [1].
|
|---|---|
| ln Vivo |
ProINDY (2.5 μM) significantly restores synchronized normal development in Xenopus laevis [1].
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: COS7 cells transfected with EGFP-Dyrk1A and EGFP-tau Tested Concentrations: 0.3, 1, 3, 10, 30 μM Incubation Duration: 20 hrs (hours) Experimental Results: Mild inhibition of tau phosphorylation at 3 μM , almost complete inhibition at 30 μM. |
| References | |
| Additional Infomation |
INDY is a member of the class of benzothiazoles that is 2,3-dihydro-1,3-benzothiazole substituted by 2-oxopropylidene, ethyl, and hydroxy groups at positions 2, 3 and 5, respectively. It is an ATP-competitive inhibitor of Dyrk1A and Dyrk1B (IC50 of 0.24 muM and 0.23 muM, respectively). It has a role as an antineoplastic agent, a drug metabolite and an EC 2.7.12.1 (dual-specificity kinase) inhibitor. It is a member of benzothiazoles, an organic hydroxy compound and an enone.
|
| Molecular Formula |
C12H13NO2S
|
|---|---|
| Molecular Weight |
235.302
|
| Exact Mass |
235.067
|
| CAS # |
1169755-45-6
|
| Related CAS # |
1169755-45-6;
|
| PubChem CID |
44136031
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
2.078
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
16
|
| Complexity |
316
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCN\1C2=C(C=CC(=C2)O)S/C1=C\C(=O)C
|
| InChi Key |
GCSZJMUFYOAHFY-SDQBBNPISA-N
|
| InChi Code |
InChI=1S/C12H13NO2S/c1-3-13-10-7-9(15)4-5-11(10)16-12(13)6-8(2)14/h4-7,15H,3H2,1-2H3/b12-6-
|
| Chemical Name |
(1Z)-1-(3-ethyl-5-hydroxy-1,3-benzothiazol-2-ylidene)propan-2-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 33.33 mg/mL (~141.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.2499 mL | 21.2495 mL | 42.4989 mL | |
| 5 mM | 0.8500 mL | 4.2499 mL | 8.4998 mL | |
| 10 mM | 0.4250 mL | 2.1249 mL | 4.2499 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02159833 | Completed | Other: Intranasal challenge with active substance (food protein) Other: Intranasal challenge with placebo |
Food Allergy | Imperial College London | 2014-10 | Not Applicable |
| NCT04681781 | Enrolling by invitation | 17p13.1 Deletions Confined to SLC13A5 Gene
SLC13A5 Deficiency Citrate Transporter Deficiency Citrate Transporter Disorder |
TESS Research Foundation | 2021-03-01 | ||
| NCT06144957 | Recruiting | SLC13A5 Deficiency Citrate Transporter Deficiency Citrate Transporter Disorder DEE25 |
2021-12-01 | TESS Research Foundation | ||
| NCT02500082 | No longer available | Drug: triheptanoin | SLC13A5 Gene Mutation Citrate Transporter Deficiency |
Irina A Anselm | ||
| NCT03964831 | Completed | Device: P200TxE Device: P200DTx |
Retinal Disease | Optos, PLC | 2019-06-18 | Not Applicable |
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
